Beclabuvir

Research use only, not for human use.

Beclabuvir (BMS-791325) is a potent allosteric inhibitor of HCV NS5B polymerase with EC50 of 6 and 3 nM for genotype 1b and 1a in FRET assays, respectively.

Beclabuvir (BMS-791325) is a potent allosteric inhibitor of HCV NS5B polymerase with EC50 of 6 and 3 nM for genotype 1b and 1a in FRET assays, respectively; inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of <30 nM; the combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1 in clinical trials.HCV Infection Phase 1 Discontinued.

Beclabuvir demonstrates additive or synergistic antiviral activity with pegIFN/RBV and in 2- or 3-drug combinations with a range of DAAs, such as HCV NS3 protease inhibitors, NS5A inhibitors' and/or nucleoside NS5B inhibitors.

The combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide.

BMS791325 | BMS-791325

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

958002-33-0

659.846

C36H45N5O5S

>98% (HPLC)

DMSO : ≥ 30 mg/mL 45.47 mM

CN1CC2CCC(C1)N2C(=O)C34CC3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8

(4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo[3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

(-20℃)

With Ice Pack

≥ 2 years